Introduction
============

An increasing number of individuals are being diagnosed with diabetes, particularly type 2 diabetes (T2D) ([@b1-ijmm-41-03-1547]). In addition to genetic factors, environmental factors contribute to the occurrence of T2D. In human and animal experiments, a negative association between intrauterine nutrition and metabolic disease risk has been observed. Hales *et al* reported a U-shaped relationship between birth weight and glucose intolerance at 64 years of age ([@b2-ijmm-41-03-1547]). Furthermore, low-birth weight subjects exhibited increased plasma levels of proinsulin, which is an indication of islet β cell dysfunction. Based on these findings, Hales and Barker proposed the \'thrifty phenotype hypothesis\', which addresses the important role of poor nutrition in early life on permanent changes in glucose-insulin metabolism, to explain this relationship ([@b3-ijmm-41-03-1547]).

Chromium (Cr) is an essential glucose regulator ([@b4-ijmm-41-03-1547],[@b5-ijmm-41-03-1547]). The normal human range of blood Cr is 0.12--0.67 *μ*g/l ([@b6-ijmm-41-03-1547]). However, total body Cr concentrations decrease by 25--40% with age. Subjects with Cr deficiency have increased blood glucose and insulin levels ([@b7-ijmm-41-03-1547]). In addition, the tissue Cr levels of patients with diabetes are lower compared with in normal control subjects, and a correlation exists between low serum Cr levels and the occurrence of T2D ([@b8-ijmm-41-03-1547]).

A previous study demonstrated that maternal Cr deficiency leads to insulin resistance (IR) and impaired glucose tolerance in WNIN rat offspring. The underlying mechanism involves increased oxidative stress ([@b9-ijmm-41-03-1547]). In addition, the molecular mechanisms underlying fetal programming may be partly associated with epigenetic regulation of the expression of key genes ([@b10-ijmm-41-03-1547]). Our recent research indicates that maternal chromium restriction leads the miRNA dysfunction involved with MAPK signaling pathway in the adipose of female offspring ([@b11-ijmm-41-03-1547]).

MicroRNAs (miRNA/miRs) are associated with important epigenetic mechanisms. miRNAs are short noncoding RNA molecules that bind to target genes to regulate various cellular processes. Increasing research has suggested that miRNAs are involved in the incidence and development of diabetes. miR-125a is upregulated in Goto-Kakizaki (GK) rats (T2D rat model) compared with in normal rats ([@b12-ijmm-41-03-1547]), and may lead to IR. In addition, increased miR-143 has been detected in the livers of diabetic rats ([@b13-ijmm-41-03-1547]); miR-143 downregulates oxysterol-binding protein-related protein 8 and subsequently impairs the ability of insulin to induce the activation of protein kinase B (AKT) signaling, a central node of insulin action to induce glucose metabolism. Upregulation of miR-181a in diabetic livers and hepatocytes decreases sirtuin 1 expression, thus inactivating insulin signaling and glucose metabolism ([@b14-ijmm-41-03-1547]). Furthermore, miR-96 and miR-126 directly target the insulin receptor substrate 1 (IRS1) 3′-untranslated region; a reduction in IRS1 is involved in IR under mitochondrial dysfunction in hepatocytes ([@b15-ijmm-41-03-1547],[@b16-ijmm-41-03-1547]). Downregulation of miR-200 also impairs AKT/glycogen synthase kinase-mediated glycogenesis in the liver, resulting in hepatic IR ([@b17-ijmm-41-03-1547]).

The present study hypothesized that an association exists between maternal low Cr (LC) status and epigenetic reprogramming of the transcriptome by means of miRNA in offspring. To test this hypothesis, a whole miRNA expression array was performed in mice exposed to maternal Cr restriction.

Materials and methods
=====================

Animals and protocol
--------------------

All procedures were performed in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institute of Health ([@b18-ijmm-41-03-1547]). The present study was approved by the Animal Care Committee of the Peking Union Medical Hospital (Beijing, China; permit no. MC-07-6004), and all efforts were made to minimize suffering. Female (n=20) and male (n=10) C57BL mice (age, 7 weeks; weight, 18.7±1.8 g) were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China; SCXK-2013-0107). All mice were maintained in ventilated individual cages at 24±1°C and had access to food and water *ad libitum*; lights were switched on between 6 a.m. and 6 p.m.. Mating was confirmed by the presence of sperm in a vaginal smear the following morning. Pregnant females (n=16) were randomly divided into two groups: Control group (CON, fed a standard rodent casein-based diet based on the American Institute of Nutrition AIN-93G diet) and LC diet group (fed a LC diet, which lacked only in Cr) (n=8/group; [Table I](#tI-ijmm-41-03-1547){ref-type="table"}). The diet protocol was maintained throughout the gestation and lactation periods. The concentration of Cr in the CON and LC diets was 1.19 and 0.14 mg Cr/kg^−1^ diet, respectively \[assessed by atomic absorption spectrometer (TAS986; Beijing Persee General Corporation, Beijing, China)\]. All diets were provided by Research Diets, Inc. (New Brunswick, NJ, USA). Following birth of the offspring, the litter size in each cage was randomly adjusted to 6 pups (3 males, 3 females, if possible) to ensure equal nutrition until the pups were weaned. Pups were kept under the same housing conditions as the adult mice. After weaning, pups were randomly subdivided into four groups: i) Pregnancy and lactation CON diet group fed a CON diet after weaning (CON/CON); ii) pregnancy and lactation CON diet group fed a LC diet after weaning (CON/LC); iii) pregnancy and lactation LC group fed a LC diet after weaning (LC/LC) and iv) pregnancy and lactation LC group fed a CON diet after weaning (LC/CON) (n=8/group; 1 male pup from each litter was randomly assigned to the experimental groups). Male offspring only were used for the present study to avoid sex differences on the effect of maternal nutrition on glucose metabolism ([@b19-ijmm-41-03-1547]). At the end of the experimental period (16 weeks of age), blood samples were collected from the intraorbital retrobulbar plexus in anesthetized mice (ketamine 100 mg/kg, i.p.; Pfizer, Inc., New York, NY, USA) following a 10-h fast. All male mice (n=8/group) from eight different litters (1 male offspring/litter) were then sacrificed. Whole livers of the offspring were quickly removed and stored at −80°C for further analysis. The experimental design is presented in [Fig. 1](#f1-ijmm-41-03-1547){ref-type="fig"}.

Measurement of serum Cr levels
------------------------------

The blood samples from the dams at weaning and the 16-week-old offspring were centrifuged and the resulting serum was collected for Cr analysis. Serum Cr concentrations were measured using an atomic absorption spectrometer (Atomic Absorption Spectrophotometer; Hitachi, Ltd., Tokyo, Japan).

Measurement of body weight and blood glucose levels
---------------------------------------------------

Body weight and blood glucose levels of dams were measured at weaning, and were measured in pups at birth, weaning and at 16 weeks of age. Tail blood glucose measurements were recorded using a blood glucose analyzer (Bayer Contour TS Glucometer; Bayer AG, Leverkusen, Germany).

Oral glucose tolerance test (OGTT)
----------------------------------

An OGTT was performed on dams at weaning and on pups at 16 weeks, after 12 h of food deprivation. The OGTT was performed in the morning. Glucose was introduced into the mice via oral gavage at a final dose of 2 g/kg body weight. Blood samples were obtained from the tail vein 30, 60 and 120 min after glucose load in order to analyze glucose concentration using a glucometer (Bayer Contour TS Glucometer; Bayer AG). Glucose responses during the OGTT were evaluated by estimating the total area under the curve (AUC) using the trapezoidal method.

Serum insulin levels and homeostasis model assessment of IR (HOMA-IR) index
---------------------------------------------------------------------------

After 12 h of food deprivation, tail blood samples were obtained and centrifuged. Serum insulin concentration was quantified using an ELISA method (mouse insulin kit; EZRMI-13K; EMD Millipore, Billerica, MA, USA) according to the manufacturer\'s protocol. Serum glucose was measured by an enzyme end-point method (Roche Diagnostics, GmnH, Mannheim, Germany). HOMA-IR was calculated as follows: Fasting serum glucose × fasting serum insulin/22.5.

RNA extraction, cDNA synthesis and miRNA array hybridization
------------------------------------------------------------

Total liver RNA was isolated using the mirVana™ RNA Isolation kit (Ambion; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol. All RNA samples were examined for the absence of DNA and RNA degradation by denaturing agarose gel electrophoresis. Total RNA was then reverse transcribed using the PrimeScript Reverse Transcription (RT) kit (Takara Bio, Inc., Shiga, Japan) according to the manufacturer\'s protocol. The expression of miRNAs contained in miRBase version 20.0 (released in June, 2013; <http://www.mirbase.org>) was analyzed by microarray using the Affymetrix Multispecies miRNA 4.0 array (Affymetrix; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Raw data were normalized, processed, and analyzed for statistical significance using Student\'s t-test and post hoc Tukey\'s test was applied for a multiple testing correction.

miRNA quantitative polymerase chain reaction (qPCR) validation
--------------------------------------------------------------

Total RNA obained using the mirVana™ RNA Isolation kit mentioned above was quantified using a NanoDrop 1000, and then reverse transcribed using TaqMan MicroRNA RT kit and RT primers from the respective TaqMan MicroRNA assay kit. qPCR was performed on an ABI 7900 thermocycler using the TaqMan Universal PCR Master Mix and TaqMan probes from the TaqMan MicroRNA assay kit (all from Applied Biosystems; Thermo Fisher Scientific, Inc.). Taqman probes were synthesized according to miRNA mature sequneces ([Table III](#tIII-ijmm-41-03-1547){ref-type="table"}). Amplification was performed at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. The reaction conditions were 16°C for 30 min, 42°C for 30 min and 85°C for 5 min. Tissue miRNA levels were normalized to endogenous U6.

miRNA target gene bioinformatics analysis
-----------------------------------------

miRTarBase database version 6.0 (released September, 2015; <http://mirtarbase.mbc.nctu.edu.tw/>) was used to perform bioinformatics analysis of the differentially expressed miRNAs and their validated target sequences ([@b20-ijmm-41-03-1547]).

miRNA target genes qPCR analysis
--------------------------------

Total RNA extracted from the liver samples using the mirVana™ RNA Isolation kit mentioned above was reverse-transcibed by Superscript II (Invitrogen; Thermo Fisher Scientific, Inc.). qPCR analysis of gene expression was performed using an ABI Prism 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers used were obtained from Applied Biosystems; Thermo Fisher Scientific, Inc. ([Table II](#tII-ijmm-41-03-1547){ref-type="table"}). Each PCR sample contained 20 ng reverse-transcribed RNA, which was analyzed using SYBR-Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following reaction conditions were used: 48°C for 30 min, 95°C for 15 min, 40 cycles of 95°C for 15 sec, 55°C for 1 min. Target mRNA expression was normalized to β-actin expression and are expressed as a relative value using the cycle quantification (Cq) method (2^−ΔΔCq^) ([@b21-ijmm-41-03-1547]).

miRNA target genes pathway analysis
-----------------------------------

To fully clarify the biological functions of the target genes of differentially expressed miRNAs, Gene Ontology (GO) classifications and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were determined, using Database for Annotation, Visualization and Integrated Discovery software (<http://david.abcc.ncifcrf>. gov/) ([@b22-ijmm-41-03-1547]). Interactions between miRNAs and mRNAs were analyzed by Cytoscape (<http://www.cytoscape.org>) ([@b23-ijmm-41-03-1547]).

Cell culture and treatments
---------------------------

HepG2 human liver cancer cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum, 1% pencillin-strepomycin, 2 mM glutamine (all from Lonza Group, Ltd., Basel, Switzerland) and 25 mM HEPES (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in a humidified incubator containing 5% CO~2~ at 37°C. HepG2 cells (2×10^5^ cells/ml) were transfected with miR-327, miR-223-3p, miR-446f-3p (mature sequences in [Table III](#tIII-ijmm-41-03-1547){ref-type="table"}; 10 *μ*M; Ambion; Thermo Fisher Scientific, Inc.) or negative control oligo-duplex (Ambion) using transfection reagent (Lipofectamine^®^ RNAiMAX; Invitrogen; Thermo Fisher Scientific, Inc.) for 12 h at 37°C. After 24 h, cells were harvested for RNA preparation, and to measure the relative expression levels of miR-327, miR-223-3p, miR-446f-3p, thymoma viral proto-oncogene 1 (*Akt1*), 3-phosphoinositide dependent protein kinase 1 (*Pdpk1*), phosphatidylinositol 3-kinase, catalytic, α polypeptide (*Pik3ca*), phosphatidylinositol 3-kinase, regulatory subunit, polypeptide (*Pik3r1*), phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 3 (*Pik3r3*) and solute carrier family 2 member 4 \[*Slc2a4*, also known as glucose transporter 4 (*Glut4*)\].

Data statistical analysis
-------------------------

All numerical results are expressed as the means ± standard deviation of the indicated number of experiments. Student\'s t-test was used to compare unpaired samples, and One-way analysis of variance followed by post hoc Tukey test was used for multiple comparisons. GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used to analyze the data. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Dams
----

Serum Cr concentrations were lower in the LC group compared with in the CON group (0.36±0.03 vs. 0.74±0.14 ng/ml, P\<0.01). Body weight, fasting blood glucose, blood glucose levels, AUC of glucose concentration during OGTT, serum insulin levels and HOMA-IR index in LC dams were similar to CON dams at the end of lactation (data not shown).

Offspring
---------

### Effect of maternal LC diet on serum Cr in offspring

At 16 weeks of age, serum Cr in the LC/LC (0.31±0.02 ng/ml) and CON/LC groups (0.27±0.01 ng/ml) was significantly reduced compared with in the CON/CON (0.69 ±0.03 ng/ml) and LC/CON groups (0.72±0.09 ng/ml, P\<0.01).

### Effects of maternal LC diet on body weight of offspring

At birth, 3 and 16 weeks of age, body weight of male pups was not markedly different among the various groups.

### Effects of maternal LC diet on fasting blood glucose in offspring

At week 3, no significant differences in fasting blood glucose were noted among all groups. At week 16, fasting blood glucose in the CON/LC (8.32±0.72 mmol/l), LC/CON (8.19±0.92 mmol/l) and LC/LC groups (8.52±0.73 mmol/l) was significantly higher compared with in the CON/CON group (5.83±0.07 mmol/l, P\<0.05).

### Effects of maternal LC diet on glucose tolerance in offspring

To determine whether maternal LC diet disturbs glucose tolerance in offspring, an OGTT was conducted at 16 weeks of age. After a bolus of oral glucose, blood glucose levels were significantly increased in the offspring of the CON/LC, LC/LC and LC/CON groups compared with in the CON/CON group at 30, 60 and 120 min (P\<0.05 or P\<0.01). AUC of blood glucose concentration was increased in the CON/LC (51.43±4.38 mmol/l/h), LC/LC (53.18±4.83 mmol/l/h) and LC/CON groups (48.85±5.28 mmol/l/h) compared with in the CON/CON group (26.23±3.14 mmol/l/h, P\<0.01).

### Effects of maternal LC diet on serum insulin and HOMA-IR index in offspring

Serum fasting insulin levels were significantly increased in the CON/LC (11.8±1.84 *μ*IU/ml) and LC/LC groups (13.2±1.8 *μ*IU/ml) compared with in the CON/CON group (6.4±0.53 *μ*IU/ml, P\<0.05). HOMA-IR index in the LC/CON (3.8±0.37), CON/LC (3.1±0.24) and LC/LC groups (3.8±0.26) was higher than that in the CON/CON group (2.1±0.13, P\<0.01) (data not shown).

miRNA array
-----------

Affymetrix miRNA 4.0 array contains all known mouse and rat miRNA annotated in the miRBase 20.0 sequence database. A volcano plot was generated to identify differential expression between the LC/CON and CON/CON groups, as shown in [Fig. 2](#f2-ijmm-41-03-1547){ref-type="fig"}. The cluster and heat maps of all detected differentially expressed miRNAs were plotted to better demonstrate differential miRNA expression between the two groups ([Fig. 3](#f3-ijmm-41-03-1547){ref-type="fig"}). The miRNA array yielded 14 significantly differentially expressed miRNAs ([Table III](#tIII-ijmm-41-03-1547){ref-type="table"}). Among the 14 significantly differentially expressed miRNAs, 8 miRNAs were upregulated (mmu-miR-122-3p, mmu-miR-6238, mmu-miR-669a-3p, mmu-miR-691, mmu-miR-223-3p, mmu-miR-327, mmu-miR-207 and mmu-miR-466f-3p), and 6 miRNAs were downregulated (mmu-miR-30f, mmu-miR-344b-5p, mmu-miR-28b, mmu-miR-296-3p, mmu-miR-7062-3p and mmu-miR-3090-5p). Differentially expressed miRNAs were defined by a fold change ≥2, up- or downregulated and P\<0.05.

qPCR
----

qPCR was used to confirm differential miRNA expression and to detect the target genes of differentially expressed miRNAs ([Fig. 4](#f4-ijmm-41-03-1547){ref-type="fig"}). The differential expression of miRNAs was confirmed by RT-qPCR; the results were consistent with the array analysis ([Fig. 4A](#f4-ijmm-41-03-1547){ref-type="fig"}).

Bioinformatics analysis
-----------------------

Based on the data from miRTar-Base databases, 8 of the 14 dysregulated miRNAs have 732 validated target genes ([Table IV](#tIV-ijmm-41-03-1547){ref-type="table"}). The significantly over-represented biological process, cellular component and molecular function GO terms (P\<0.001) in the differentially expressed miRNA targets are presented in [Table V](#tV-ijmm-41-03-1547){ref-type="table"}. In biological process, the GO terms were involved with transcription, regulation of transcription, negative regulation of gene expression, protein localization, regulation of neuron apoptosis, phosphate metabolic process and phosphorus metabolic process ([Fig. 5](#f5-ijmm-41-03-1547){ref-type="fig"}). A pathway analysis was conducted using the 8 differentially expressed miRNA targets; pathway title and the P-value of the significant pathways (P\<0.0001), are presented in [Table VI](#tVI-ijmm-41-03-1547){ref-type="table"}. KEGG pathway analysis showed that the target genes of differential expression miRNAs in LC/CON mice were mainly focused on insulin signaling pathway ([Fig. 6](#f6-ijmm-41-03-1547){ref-type="fig"}). miRNAs and their target interactions are presented in [Fig. 7](#f7-ijmm-41-03-1547){ref-type="fig"}.

miRNA target genes qPCR
-----------------------

*Akt1*, *Pdpk1*, *Pik3ca*, *Pik3r1*, *Pik3r3* and *Slc2a4* (*Glut4*) were downregulated in the LC/CON group compared with in the CON/CON group, as demonstrated by RT-qPCR ([Fig. 4B](#f4-ijmm-41-03-1547){ref-type="fig"}).

miR-327, miR-223-3p and miR-466f-3p target the insulin signaling pathway in HepG2 cells
---------------------------------------------------------------------------------------

To determine whether miR-327, miR-223-3p and miR-466f-3p negatively regulate the insulin signaling pathway *in vitro*, HepG2 cells were transfected with miR-327, miR-223-3p and miR-466f-3p mimics. *Slc2a4* expression was significantly downregulated in miR-327-transfected HepG2 cells (P\<0.01; [Fig. 8A](#f8-ijmm-41-03-1547){ref-type="fig"}). In miR-466f-3p-transfected HepG2 cells, *Pik3ca* and *Pik3r1* were significantly downregulated (P\<0.01; [Fig. 8B](#f8-ijmm-41-03-1547){ref-type="fig"}). In miR-223-3p-transfected HepG2 cells, *Akt1*, *Pdpk1* and *Pik3r3* were significantly downregulated (P\<0.01; [Fig. 8C](#f8-ijmm-41-03-1547){ref-type="fig"}).

Discussion
==========

In the present study, a 13-week LC diet led to impaired fasting blood glucose and glucose tolerance, and IR in male mice. Previous studies revealed the key role of Cr in regulating blood glucose ([@b24-ijmm-41-03-1547],[@b25-ijmm-41-03-1547]). In addition, Cr supplementation has been reported to improve glucose metabolism in diabetic rats and patients ([@b26-ijmm-41-03-1547]--[@b28-ijmm-41-03-1547]).

Notably, the present study demonstrated that male offspring from dams fed a LC diet had comparable birth weight to the CON group up to 16 weeks. A maternal LC diet did not change fasting blood glucose levels in offspring at 3 weeks of age; however, offspring from dams fed a LC diet exhibited impaired fasting blood glucose and glucose tolerance at 16 weeks of age. Mice in the LC/CON group had normal serum Cr levels; however, this could not correct the glucose intolerance. Padmavathi *et al* indicated that maternal Cr restriction increased fasting plasma glucose (from 9 months) and the AUC of glucose concentration during OGTT (from 15 months) in the offspring ([@b9-ijmm-41-03-1547]). In addition, growth-restricted rats exhibited glucose intolerance from 6 months of age ([@b29-ijmm-41-03-1547]). Pups from magnesium-restricted dams, which were shifted to a control diet, exhibited glucose intolerance at 180 days of age ([@b30-ijmm-41-03-1547]). A low-protein diet increased fasting blood glucose in offspring at 3 months ([@b31-ijmm-41-03-1547]). The results of the present study detected glucose intolerance in offspring earlier than Padmavathi *et al* ([@b9-ijmm-41-03-1547]), this may be partly because the Cr-restricted diet used in the present study was 88% Cr restriction compared with 67% Cr restriction.

The present study also demonstrated that serum insulin levels and HOMA-IR index were markedly increased in the offspring of dams fed a LC diet at 16 weeks of age. Padmavathi *et al* reported that maternal Cr restriction increased fasting insulin (from 15 months) and HOMA-IR index (from 9 months), whereas rehabilitation could not correct this effect ([@b9-ijmm-41-03-1547]). In a previous study, pups from pregnant rats fed a calcium-deficient diet exhibited increased insulin levels and HOMA-IR index at day 200 ([@b32-ijmm-41-03-1547]). Furthermore, at 12 months of age, offspring from vitamin B12-restricted dams had higher fasting blood insulin levels and HOMA-IR index ([@b31-ijmm-41-03-1547]).

Using a miRNA array and qPCR, the present study indicated that a maternal LC diet downregulated miR-334b-5p expression in the liver of male offspring. Zeng *et al* revealed that miR-344-3p was downregulated in islets from diabetic GK rats ([@b33-ijmm-41-03-1547]). Furthermore, in the present study, a maternal LC diet downregulated miR-296-3p expression in the liver of male offspring. In the pancreatic β-cell line, MIN6, miR-296 was significantly downregulated by high glucose treatment ([@b34-ijmm-41-03-1547]). In addition, a maternal LC diet upregulated miR-122-3p expression in the liver of male offspring; miR-122 is highly expressed in the liver and is highly conserved in sequence ([@b35-ijmm-41-03-1547]). Serum miR-122 levels are markedly increased in newly diagnosed diabetic cats ([@b36-ijmm-41-03-1547]). A maternal LC diet also upregulated miR-327 expression in the liver of male offspring. miR-327 has been revealed to be upregulated in myocardial microvascular endothelial cells from GK rats compared with Wistar rats ([@b36-ijmm-41-03-1547]).

In the present study, further bioinformatics analysis aided in the interpretation of the biological function of the differentially expressed miRNAs in glucose metabolism regulation. According to the KEGG pathway enrichment analysis, the significantly differentially expressed miRNAs (miR-327, miR-223-3p and miR-466f-3p) in the LC/CON group served important roles in the insulin signaling pathway.

In the insulin signaling pathway, *Pik3r1* and *Pik3ca* are target genes of miR-466f-3p ([@b37-ijmm-41-03-1547]--[@b39-ijmm-41-03-1547]). In addition, *Akt1* and *Pik3r3* are target genes of miR-223-3p ([@b40-ijmm-41-03-1547]). One target of miR-327 is *Slc2a4* (*Glut4*) ([@b39-ijmm-41-03-1547]). In a previous study, Cr malate improved *Glut4* and *Akt* levels in the liver tissues of T2D rats ([@b26-ijmm-41-03-1547]). In C2C12 skeletal muscle cells, oligomannuronate Cr complexes may enhance GLUT4 and the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway ([@b25-ijmm-41-03-1547]). Therefore, it may be hypothesized that a maternal LC diet upregulates miR-327, miR-466f-3p and miR-223-3p expression, thus inhibiting insulin signaling ([Fig. 9](#f9-ijmm-41-03-1547){ref-type="fig"}).

The PI3K/AKT signaling pathway is a classical pathway that regulates insulin in glucose metabolism. This pathway serves a role in glucose uptake by the liver, skeletal muscles and adipose tissues ([@b41-ijmm-41-03-1547],[@b42-ijmm-41-03-1547]). The insulin receptor signaling pathway contributes to the development of diabetes. The IRS-1/PI3K/Akt axis has an important role in the insulin receptor signaling pathway through cascade phosphorylation ([@b43-ijmm-41-03-1547],[@b44-ijmm-41-03-1547]). Inhibiting or blocking this pathway may reduce the physiological effects of insulin, which lead to IR. Ye *et al* demonstrated that hepatocytes in intrauterine growth retardation rats with catch-up growth exhibited decreased IRS1 and PI3K expression ([@b45-ijmm-41-03-1547]). In addition, the PI3K p110β subunit, Akt1 proteins and phosphorylated-Akt Ser473 are reduced in the offspring of low protein-fed dams ([@b46-ijmm-41-03-1547]). A previous study also reported that maternal protein restriction leads a decrease in Akt1 (Ser473) phosphorylation in the livers of offspring at postnatal day 130 ([@b47-ijmm-41-03-1547]). Catch-up growth following intrauterine growth restriction reduces the expression of the PI3K p110β subunit at 22 days old, and Akt phosphorylation and Akt-2 protein levels at 3 months in adipose tissue ([@b48-ijmm-41-03-1547]). In addition, maternal diabetes has been revealed to decrease GLUT4 in the adipose and muscle tissues of 10-week-old male offspring ([@b49-ijmm-41-03-1547]).

In conclusion, the present study confirmed that a maternal LC diet caused glucose intolerance and IR in male offspring. The present study is the first, to the best of our knowledge, to demonstrate that a maternal LC diet induces miRNA dysfunction in the liver samples of offspring. In particular, a maternal LC diet may upregulate the expression of miR-327, miR-466f-3p and miR-223-3p, thus inhibiting the insulin signaling pathway in male offspring. In the future, scientists should aim to identify interventions for maternal Cr restriction to affect glucose metabolism in offspring. This treatment will benefit mothers and the next generation.
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![Animal experimental design. miRNA, microRNA; PCR, polymerase chain reaction.](IJMM-41-03-1547-g00){#f1-ijmm-41-03-1547}

![Volcano plot of the miRNA microarray analysis. Volcano plots are used to visualize differential expression patterns between two groups. Vertical lines correspond to 2-fold up- and downregulation, and the horizontal line represents P=0.05. miR/miRNA, microRNA.](IJMM-41-03-1547-g01){#f2-ijmm-41-03-1547}

![Hierarchical clustering of the differentially expressed miRNAs in the LC/CON group compared with in the CON/CON group. Left, miRNA clustering tree; top, sample clustering tree. Red indicates high relative expression, and green indicates low relative expression. L9, L10 and L11 belong to the LC/CON group; L74, L93 and L97 belong to the CON/CON group. CON, control; LC, low chromium; miRA/miR, microRNA.](IJMM-41-03-1547-g02){#f3-ijmm-41-03-1547}

![Differential miRNA expression underwent (A) qPCR validation and (B) target genes of the differentially expressed miRNAs were detected by qPCR. Data are presented as the means ± standard deviation, n=8. ^\*\*^P\<0.01 vs. the CON/CON group. *Akt1*, thymoma viral proto-oncogene 1; CON, control; LC, low chromium; miR/miRNA, microRNA; *Pdpk1*, 3-phosphoinositide dependent protein kinase 1; *Pik3ca*, phosphatidylinositol 3-kinase, catalytic, α polypeptide; *Pik3r1*, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide (p85 α); *Pik3r3*, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 3 (p55); qPCR, quantitative polymerase chain reaction; *Slc2a4*, solute carrier family 2 member 4.](IJMM-41-03-1547-g03){#f4-ijmm-41-03-1547}

![Gene Ontology analysis of the miRNA target genes in biological process.](IJMM-41-03-1547-g04){#f5-ijmm-41-03-1547}

![Differentially expressed miRNA gene targets in the insulin signaling pathway. Red represents upregulation; green represents downregulation.](IJMM-41-03-1547-g05){#f6-ijmm-41-03-1547}

![miRNA-gene network contains six miRNAs and their target genes, which are involved in the insulin signaling pathway. Yellow triangular nodes represent miRNA, blue rectangular nodes represent mRNA. Edges describe the inhibitory effect of miRNA on mRNA. miR/miRNA, microRNA.](IJMM-41-03-1547-g06){#f7-ijmm-41-03-1547}

![(A--C) Quantitative polymerase chain reaction analysis of miR-327, miR-466f-3p, miR-223-3p, *Akt1*, *Pdpk1*, *Pik3ca*, *Pik3r1*, *Pik3r3* and *Slc2a4* expression in miR-327-, miR-466f-3p- and miR-223-3p-transfected HepG2 cells. Data are presented as the means ± standard deviation, n=3. ^\*\*^P\<0.01 vs. the NC group. *Akt1*, thymoma viral proto-oncogene 1; miR/miRNA, microRNA; NC, negative control; *Pdpk1*, 3-phosphoinositide dependent protein kinase 1; *Pik3ca*, phosphatidylinositol 3-kinase, catalytic, α polypeptide; *Pik3r1*, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide (p85 α); *Pik3r3*, phos-phatidylinositol 3-kinase, regulatory subunit, polypeptide 3 (p55); *Slc2a4*, solute carrier family 2 member 4.](IJMM-41-03-1547-g07){#f8-ijmm-41-03-1547}

![Possible underlying mechanism of miRNA-regulatory networks. Insulin binding to its receptor induces receptor tyrosine autophosphorylation and activation of IRSs/PI3K/Akt signaling pathways. Modulation of gene expression is indicated by black arrows. Akt, protein kinase B; *Akt1*, thymoma viral proto-oncogene 1; GLUT4, glucose transporter 4; IRS, insulin receptor substrate; miR/miRNA, microRNA; *Pdpk1*, 3-phosphoinositide dependent protein kinase 1; PI3K, phosphatidylinositol 3-kinase; *Pik3ca*, phosphatidylinositol 3-kinase, catalytic, α polypeptide; *Slc2a4*, solute carrier family 2 member 4.](IJMM-41-03-1547-g08){#f9-ijmm-41-03-1547}

###### 

Composition of diets[a](#tfn1-ijmm-41-03-1547){ref-type="table-fn"}.

  Ingredient (g or mg/kg diet)                         CON     LC
  ---------------------------------------------------- ------- -------
  Cornstarch, g                                        397.5   397.5
  Casein, g                                            200.0   200.0
  Dextrinized cornstarch, g                            132.0   132.0
  Sucrose, g                                           100.0   100.0
  Soybean oil, g                                       70.0    70.0
  Fiber, g                                             50.0    50.0
  Mineral mix, g                                       35.0    35.0
  Vitamin mix AIN-93-VX, g                             10.0    10.0
  L-Cystine, g                                         3.0     3.0
  Choline bitartrate, g                                2.6     2.6
  Tert-butylhydroquinone, mg                           14.0    14.0
  Chromium potassium sulfate 12H~2~O (10.42% Cr), mg   275.0   0.0

Reeves ([@b50-ijmm-41-03-1547]); CON, control; LC, low chromium.

###### 

Quantitative polymerase chain reaction primers.

  Gene symbol   ID             Forward                     Reverse                      Product length (bp)
  ------------- -------------- --------------------------- ---------------------------- ---------------------
  *Akt1*        NM_009652      5′-CAGTTTGAGACCACACAT-3′    5′-GCGTCAGTCCTTAATAGTT-3′    75
  *Pdpk1*       NM_011062      5′-GGAATTGAATAGTGAGGTT-3′   5′-AATGATGAATGTTGTATGTG-3′   114
  *Pik3ca*      NM_008839      5′-TGTGGCATCTGAGTATCT-3′    5′-TGTGGCATCTGAGTATCT-3′     132
  *Pik3r1*      NM_001077495   5′-ATTAAGGTTCTGTGGATTC-3′   5′-GCTATGCTGTATCTATCTG-3′    80
  *Pik3r3*      NM_181585      5′-ATTGGAATACCTGTGACT-3′    5′-TGACTTACTTGGAAGAGAT-3′    148
  *Slc2a4*      NM_009204      5′-TATGTTGCGGATGCTATG-3′    5′-TTAGGAAGGTGAAGATGAAG-3′   82

*Akt1*, thymoma viral proto-oncogene 1; *Pdpk1*, 3-phosphoinositide dependent protein kinase 1; *Pik3ca*, phosphatidylinositol 3-kinase, catalytic, α polypeptide; *Pik3r1*, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide (p85 α); *Pik3r3*, phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 3 (p55); *Slc2a4*, solute carrier family 2 member 4.

###### 

Significantly differentially expressed miRNAs in the livers of offspring from dams fed a low chromium diet.

  MicroRNA          Fold change   Regulation   P-value       Mature sequences
  ----------------- ------------- ------------ ------------- -------------------------
  mmu-miR-30f       0.4549        Down         0.000241      GUAAACAUCCGACUGAAAGCUC
  mmu-miR-344b-5p   0.4134        Down         3.56×10^−5^   AGUCAGGCUCCUGGCUAAAGUUC
  mmu-miR-28b       0.2847        Down         3.45×10^−6^   AGGAGCUCACAAUCUAUUUAG
  mmu-miR-296-3p    0.3765        Down         0.000718      GAGGGUUGGGUGGAGGCUCUCC
  mmu-miR-7062-3p   0.4833        Down         0.001047      ACUAACUUCUCCUGGCCCCACAG
  mmu-miR-3090-5p   0.4811        Down         0.000773      GUCUGGGUGGGGCCUGAGAUC
  mmu-miR-122-3p    3.0022        Up           0.000983      AAACGCCAUUAUCACACUAA
  mmu-miR-6238      2.7639        Up           0.001775      UUAUUAGUCAGUGGAGGAAAUG
  mmu-miR-669a-3p   2.1272        Up           0.007318      ACAUAACAUACACACACACGUAU
  mmu-miR-691       2.4515        Up           8.43×10^−5^   AUUCCUGAAGAGAGGCAGAAAA
  mmu-miR-223-3p    2.5277        Up           0.000156      UGUCAGUUUGUCAAAUACCCCA
  mmu-miR-327       2.9025        Up           0.000762      ACUUGAGGGGCAUGAGGAU
  mmu-miR-207       2.2873        Up           0.000728      GCUUCUCCUGGCUCUCCUCCCUC
  mmu-miR-466f-3p   2.1942        Up           1.06×10^−5^   CAUACACACACACAUACACAC

miR/miRNA, microRNA.

###### 

Validated target genes of 8 differentially expressed miRNAs[a](#tfn4-ijmm-41-03-1547){ref-type="table-fn"}.

  miRNA             Regulation   Target genes
  ----------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  mmu-miR-28b       Down         Slc7a2, Nr3c1, Timm17b, Timm17b, 2010109I03Rik, Tars2, Sl×1b, Tns4, Prss43, Pld5, Ccdc78, Tmppe
  mmu-miR-296-3p    Down         Ctla2a, Gna14, Igf1r, Dusp8, Tfam, Tnf, Cxcl11, Car5b, Nsa2, Clvs1, Phf14, Phf14, Braf, Mcmdc2, Prss43
  mmu-miR-669a-3p   Up           Cry2, Cd47, Kras, Shh, Zfp37, Rnf11, Ccdc82, 2610002M06Rik, Wdfy3, 1700019G17Rik, Fam159b, Cml2, Arrdc3, Sipa1l1, Csde1, Gm4944, Gm7616
  mmu-miR-691       Up           Cbln2, Cdk7, Inpp5d, Ndrg1, Sp4, Pcgf2, Scd3, Arl6ip1, Wtap, Atp2b1, 1700025G04Rik, Sik3, Dapl1, Adamtsl1, Utp23, Cnnm1, Hlcs
  mmu-miR-223-3p    Up           Abca1, Slc33a1, Macf1, Ank3, Prdx6, Aplp2, Atp9a, Atrn, Pcdh15, Casp9, Cbx5, Cckbr, Cdkn1b, Celf1, Dag1, Ddn, Enc1, Eps15, Ercc3, F2r, F3, Fmn1, Srgap2, Fut9, Gabra6, Gabrg1, Gria2, Grin2b, Trip12, Gzmb, Sdc2, Igf1r, Itgb1, F11r, Kcnj10, Kcnj3, Kif1b, Klf12, Kpna1, Kras, Ktn1, Ldlr, Zbtb7a, Smad5, Mecp2, Mef2c, Mt2, Map1b, Myo1c, Napb, Nf1, Nfib, Ntrk2, Dusp8, Pdgfra, Enpp1, Pdpk1, Pea15a, Peg3, Pgr, Phka1, Pik3r3, Prkcb, Pkia, Plod1, Plxna2, Prkar2b, Prnp, Ptpru, Pvt1, Rest, Rgs2, Xpr1, Rtn3, Scd1, Scn8a, Sdpr, Sept8, Serf1, Sox6, Stat3, Syn1, Syp, Syt4, Tnfaip1, Utrn, Vim, Xpc, Ywhaz, Zfp26, Akt3, Apc2, Ets1, Gm16515, Gnpda1, Mapk10, B3galt1, B3galnt1, Syn3, Trp53bp1, Amot, Nrep, Ubfd1, Mga, Rnf11, Fbxw7, Tmod2, Mfhas1, Tmx4, Sgsm1, Pgrmc1, Stk39, Vti1a, Gria3, Rragc, Ptbp2, Ak3, Ptpn9, Dbn1, Socs5, Foxo3, Rnf14, Mbnl1, Jph3, Extl2, Fam13a, Usp14, Gprc5b, Txndc12, Tmem57, Cyb5b, Rnf220, Asf1b, Ddx17, Slc25a46, Polr3g, Gpatch2, Tmem33, Camsap2, Atp2b1, Tmem178, Ndnf, Ankra2, Pdrg1, 1190002N15Rik, Abhd13, Zfp467, Sec62, Ttc9, Zfp619, Afap1, Gcc2, Draxin, Spag9, Fmnl2, Ap2b1, Klhl5, March8, Pdia6, Antxr2, Zcchc24, Dusp11, Slc37a3, Fbxl20, Usp36, Ttc4, Mvb12b, Dnajc6, Tppp, Ccnt2, 3110043O21Rik, Gpbp1, 1700012B15Rik, Lonrf3, Arl5a, Rap2a, Car12, Paqr4, Clasp2, Usp42, Golga1, Atg16l1, Kidins220, Myh10, Yipf6, Trappc6b, Mvp, Acap2, Ankrd17, Cacng7, Smarcd2, Pard6g, Vangl2, Trim9, Gopc, Dgcr8, Cadm3, Pds5b, Tbc1d14, Akap9, Inpp5f, Bbs4, Dnm3, Arrdc3, Epdr1, Ypel1, Tm9sf3, Grm7, Foxp1, Dnajc9, Jmjd1c, Fam73b, Ank2, Zfp91, Shroom2, Hlcs, Derl2, Fam57a, Ube3b, Hpcal4, Mtmr4, Zfp704, Glcci1, Mlc1, Cd99l2, Prpf8, Phf21a, Mical3, C2cd2, Rsrc2, Cblb, Daam1, Cpeb3, Prrt3, Kbtbd2, Dennd6a, Kmt2a, Gnptg, L3mbtl2, Rhbdl1, Vezt, Tom1l2, Hlf, 4933426M11Rik, Pacs2, Rasa1, Srek1, Spata13, Xkr6, Pcdh17, Golgb1, Cep120, Fam78b, Cdc42bpa, Ino80d, Camk1d, Sestd1, Zmynd8, 4932438A13Rik, Tnrc18, Vopp1, Eva1a, Mob1a, Ppp4r2, Luzp2, Arglu1, Psd3, Atg4d, Ago1, Nxt2, Eml6, Usp32, Pnma2, Phf20l1, Mb21d2, Gpr158, Rbm45, Lrrc55, Tspyl3, Podn, Wasf2, Stard13, Kat6a, Mllt6, Lgi2, Lsamp, Robo2, Caskin1, Luzp1, Nceh1, Zbtb39, Mdga2, Zhx3, Pitpnm3, Fnip2, Tmem67, Slc5a6, Dock1, Ksr2, Pcdhac1, Nefh, Lonrf2, Rbm33, Znrf3, Adcy1, Bdp1, Tnik
  mmu-miR-327       Up           Clk4, Mef2c, Ptprb, Slc2a4, Cntnap2, Fam168b, Cep68, Evi2b, Zmym5, Rasal2, Rab39, Pld5
  mmu-miR-207       Up           Adcy6, Cplx2, Emp2, Gda, Itgam, Lpl, Nab1, Nrl, Pigr, Prlr, Slc22a12, Ubtf, Txnl4a, Preb, Sh3bgrl, Rab3c, Ascl4, Prr5l, Steap2, Crebrf, BC021785, Plcl1, Ntm, Gm4944, Prkag3, Dzank1, Oacyl
  mmu-miR-466f-3p   Up           Adam9, Adcyap1r1, Akap2, Ap1g1, Xiap, Arf3, Zfhx3, Atf2, Atp7a, Pcdh15, Chic1, Bsn, Chek1, Cnr1, Cpd, Cry2, Drp2, E2f1, Efnb2, Eif2s1, Dmtn, Epha4, Ereg, Eya1, Fech, Gnb4, Grb2, Grik3, Hist1h1d, Foxq1, Hiat1, Hk2, Id2, Ids, Il17ra, Inpp5d, Jag2, Kcna4, Klra2, Hivep3, Loxl3, Mef2a, Mmp12, Mmp11, Mtf1, Nck2, Nfatc2, Nodal, Ints6, Npy1r, Slc11a2, Nrf1, Nrg3, Nrp2, Pappa, Piga, Pik3ca, Pik3r1, Prkcb, Plau, Prrx1, Ppargc1a, Pter, Ptp4a2, Ptprk, Rai1, Rgl1, Msr1, Cxcl5, Sin3a, Slc12a2, Smarca4, Spta1, Tcf4, Tcf7l2, Tcte1, Tll1, Tlr4, Tnfrsf11a, Trhr, Unc5c, Uty, Vegfa, Wfs1, Xk, Pcgf2, Zbtb7b, Ikzf2, Gtf2h2, Dnajb6, Rnasel, Sept3, Taf7, Ldb3, Cops7b, Azi2, Sytl4, Csnk1e, Prl5a1, Vps26a, Fbxl17, Sept11, Hif3a, B3gnt2, Diap2, Usp27×, Pitpnb, Pias1, Gsk3b, Akap10, Plag1, Gmeb1, Tbx20, Piwil2, Usp29, Cd200r1, Pard6b, Fign, Ms4a4b, Wtap, Ms4a4c, Gpr85, Mrps24, Dimt1, Haus2, Ccdc82, Atg10, Slc16a9, Slc25a46, Klhl13, Zfp169, Nacc2, Pdf, Golt1a, Rraga, Fndc1, Anln, Synpo2l, Phtf2, Casz1, Sash1, Mllt3, Tbc1d13, Rufy2, Prss22, Pgm2l1, Foxn3, Tmem25, Smug1, Mtfr2, Nup93, Cyb5r1, Ccpg1, Slc16a10, Ints8, Zfp444, Tmem161b, Zfp839, Appl1, Insig2, Larp1, Ddit4l, Rap2b, Ehhadh, Ubap2l, Ifitm7, Mdga1, Uhrf1bp1l, Dusp18, Arhgap12, Fam227a, Dcaf17, Sl×1b, Ppp1r14c, Abca6, Rtf1, Fam101b, B3gat1, Bcas1, Crebrf, Csrnp3, Cdk19, Clca2, Tbl1xr1, Tfcp2l1, Tdrd1, Pde4dip, Tas1r3, Mcam, Spock2, Arid4b, Hecw1, Ubac1, Lrrc19, Zfand2a, Zfp518b, Fbxl14, Adamts9, Dennd4a, Slc6a8, Dnm3, Unc5a, Ssr1, Mylk, Ston2, Trmt10a, Fam212b, Prr5, Lmx1a, Scn2a1, Erc1, Slc28a3, Rasa2, Pofut1, Asb13, Bbc3, Edaradd, Rwdd4a, Ash1l, Wfdc12, Ell2, Bzrap1, Prrg3, Ido2, Mkx, Alkbh1, Fam46a, Gabpb2, Armc2, Arhgef11, Tnrc6b, Tet2, Fam168b, BC003965, Tmprss13, Phactr2, Kctd11, Spag7, Evi2b, Rnf157, Nploc4, Stxbp6, Cep170b, Gxylt1, Tbc1d24, Cep76, Plcl1, Rabgap1, Cytip, Atp5g3, Mavs, Hnrnpa3, Bcl2l15, Slc6a17, Strip1, Cdc14a, Tmem201, Lin54, Oas1e, BC030336, Fus, Tpte, Psd3, Ankle1, Fhod1, Stard8, Ofd1, Zc3h12d, C2cd4c, Ric8b, Btnl9, Pfas, Fam160b2, Apol8, Rtp1, 9930021J03Rik, Zbtb34, Zbtb6, Lzts3, Dzank1, Zfp462, Klhl21, Rsbn1l, Ugt2b35, Ppm1k, Lonrf1, Cwf19l2, Zscan4c, Tbx22, Klf8, Atxn7, Oas3, Srgap3, Alkbh5, Greb1, Fam107a, Ctif, Nbeal1, Ss18l1, Lhfpl4, Fat3, Bpifc, Trim12c, Fndc3a, Hif1an, Itpripl2, A630001G21Rik, Zbtb39, Adrbk2, Hook3, Rnf152, Hist4h4, Ubn2, Fam169a, Sycp2, Ccdc169, Arl4c, Xpnpep3, Slfn5, Gfod1, Mast4, Skint7, Zfp516, Acot11, Taok3, Opcml, Gpd1l, Jhdm1d, Lin28b, Gm1587, Tbc1d22b, Arl14epl, Gse1, Mtx3, Zfp874b, Gm13476, Ociad2, Tmem178b, Fam169b, Scrt2, Zscan4d, Mast3, Zfp872, Zfp963, Zfp827, I830012O16Rik, AK010878

Validated target genes in miRTarBase database version 6.0. miR/miRNA, microRNA.

###### 

Gene Ontology terms significantly over-represented in the differentially expressed miRNA target genes in three separate domains (P\<0.001).

  Term                                           DE Count   Fold enrichment   P-value       Ontology
  ---------------------------------------------- ---------- ----------------- ------------- --------------------
  Transcription                                  92         1.4456            2.06×10^−4^   Biological Process
  Regulation of transcription                    110        1.3753            2.80×10^−4^   Biological Process
  Negative regulation of gene expression         30         2.0373            3.87×10^−4^   Biological Process
  Protein localization                           46         1.7009            5.17×10^−4^   Biological Process
  Regulation of neuron apoptosis                 11         3.8285            5.53×10^−4^   Biological Process
  Phosphate metabolic process                    51         1.6397            5.66×10^−4^   Biological Process
  Phosphorus metabolic process                   51         1.6397            5.66×10^−4^   Biological Process
  Transcription                                  92         1.4456            2.06×10^−4^   Biological Process
  Plasma membrane                                140        1.3912            9.85×10^−6^   Cellular Component
  Cell fraction                                  41         1.9865            4.33×10^−5^   Cellular Component
  Plasma membrane part                           86         1.5208            5.55×10^−5^   Cellular Component
  Insoluble fraction                             37         2.0236            7.68×10^−5^   Cellular Component
  Membrane fraction                              36         2.0384            8.46×10^−5^   Cellular Component
  Synapse                                        24         2.1726            7.18×10^−4^   Cellular Component
  Neuron projection                              20         2.3573            8.54×10^−4^   Cellular Component
  Cell junction                                  31         1.9046            9.00×10^−4^   Cellular Component
  Clathrin-coated vesicle                        12         3.3320            9.14×10^−4^   Cellular Component
  GTPase regulator activity                      30         2.3798            2.57×10^−5^   Molecular Function
  Nucleoside-triphosphatase regulator activity   30         2.3409            3.49×10^−5^   Molecular Function
  Transition metal ion binding                   126        1.3835            5.71×10^−5^   Molecular Function
  Metal ion binding                              173        1.2868            6.86×10^−5^   Molecular Function
  Ion binding                                    176        1.2812            7.24×10^−5^   Molecular Function
  Cation binding                                 173        1.2752            1.15×10^−4^   Molecular Function
  GTPase activator activity                      19         2.8339            1.33×10^−4^   Molecular Function
  Protein tyrosine phosphatase activity          13         3.6860            1.99×10^−4^   Molecular Function
  Zinc ion binding                               103        1.4012            2.31×10^−4^   Molecular Function
  Cytoskeletal protein binding                   30         2.0752            2.87×10^−4^   Molecular Function
  DNA binding                                    89         1.4310            3.63×10^−4^   Molecular Function

DE count, differential expression count.

###### 

Significant pathways of the dysregulated miRNA target genes (P\<0.0001).

  Pathway                      Count   Fold enrichment   P-value
  ---------------------------- ------- ----------------- -------------
  Endometrial cancer           13      7.5104            7.94×10^−8^
  Colorectal cancer            15      5.2398            6.60×10^−7^
  ErbB signaling pathway       15      5.1796            7.64×10^−7^
  Non-small cell lung cancer   12      6.6759            1.08×10^−6^
  Prostate cancer              15      5.0069            1.17×10^−6^
  Insulin signaling pathway    18      3.9185            2.41×10^−6^
  Glioma                       11      5.1634            3.99×10^−5^
